Search Within

Genitourinary Oncology Service

Formats
  1. Journal Article (2795)
  2. Meeting Abstract (2526)
  3. Review (121)
  4. Book Section (83)
  5. Editorial (57)
  6. Correspondence (34)
  7. Conference Paper (29)
  8. Guidelines (25)
  9. Research Letter (18)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Solid Tumor Oncology Division (5696)
  2. Department of Medicine (5686)
  3. GSK Faculty (1659)
  4. Human Oncology and Pathogenesis Program (1158)
  5. Department of Pathology and Laboratory Medicine (1130)
  6. Surgery (1021)

More Groups

People
  1. Robert Motzer (1252)
  2. Howard Scher (1133)
  3. David Solit (786)
  4. Dean Bajorin (664)
  5. Michael Morris (588)
  6. Jonathan Rosenberg (525)

More People

Years
  1. 2025 (204)
  2. 2024 (294)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1713)
  2. Annals of Oncology (304)
  3. Clinical Cancer Research (283)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (123)

More Publications

Publishers
  1. American Society of Clinical Oncology (1780)
  2. American Association for Cancer Research (690)
  3. Oxford University Press (414)
  4. Elsevier Science, Inc. (396)
  5. Elsevier Inc. (380)
  6. Nature Publishing Group (304)

More Publishers

Results (5696)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Treatment patterns and outcomes in "real world" patients (pts) with metastatic urothelial cancer (UC)
    Meeting Abstract

    Galsky, M. D.; Chowdhury, S.; Bellmunt, J.; Wong, Y. N.; Recine, F.; Pal, S. K.; Moshier, E. L.; Ladoire, S.; De Giorgi, U.; Yu, E. Y.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Results from a phase I study of enzalutamide in combination with docetaxel in men with prostate cancer
    Meeting Abstract

    Fleming, M. T.; Rathkopf, D. E.; Gibbons, J.; Peterson, A. C.; Hannah, A.; Forer, D.; Scher, H. I.; Morris, M. J.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Paclitaxel, ifosfamide, and cisplatin (TIP) efficacy for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT)
    Meeting Abstract

    Feldman, D. R.; Hu, J.; Dorff, T. B.; Patil, S.; Van Alstine, L. J.; Momen, L.; Carousso, M.; Hughes, A.; Snively-Solomon, J.; Ketchens, C.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • A phase I study of the safety and pharmacokinetics of DSTP3086S, an anti-STEAP1 antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Danila, D. C.; Szmulewitz, R. Z.; Higano, C. S.; Gilbert, H.; Kahn, R. S.; Wood, K.; Agarwal, P.; Lin, K.; Kabbarah, O.; Fine, B. M.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel
    Meeting Abstract

    Chi, K. N.; San Kheoh, T.; Ryan, C. J.; Molina, A.; Bellmunt, J.; Vogelzang, N. J.; Rathkopf, D. E.; Fizazi, K.; Kantoff, P. W.; Li, J.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Computer-aided bone scan lesion area quantitation: Inter-reader measurement variability
    Meeting Abstract

    Chu, G. H.; Brown, M. S.; Kim, H. J.; Kaplan, A.; Yang, K.; Allen-Auerbach, M.; Poon, C.; Levine, B.; Schiepers, C.; Verma, R.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • First-in-human phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide (LNA-ASO) to androgen receptor (AR) mRNA in patients with castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Bianchini, D.; Omlin, A. G.; Pezaro, C. J.; Mukherji, D.; Estelles, D. L.; Zivi, A.; Ferraldeschi, R.; Crespo, M.; Buchbinder, A.; Attard, G.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • A phase II trial of the aurora kinase A inhibitor MLN8237 in patients with metastatic castrate resistant and neuroendocrine prostate cancer
    Meeting Abstract

    Beltran, H.; Rubin, M. A.; Mosquera, J. M.; Christos, P. J.; Calukovic, O.; Karpenko, I.; Pinski, J. K.; Danila, D. C.; Nanus, D. M.; Tagawa, S. T.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Targeted therapy for renal cell carcinoma (RCC) with brain metastasis: Overall survival (OS) and safety
    Meeting Abstract

    Bastos, D. A.; Molina, A. M.; Jia, X.; Velasco, S.; Patil, S.; Voss, M. H.; Feldman, D. R.; Motzer, R. J.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Preliminary safety, product parameters, and immune response assessments from a phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy (ACI), in patients (pts) with surgically resected HER2+ urothelial cancer (UC) at high risk for recurrence
    Meeting Abstract

    Bajorin, D. F.; Sharma, P.; Lerner, S. P.; Sims, R. B.; Sanders, A.; DeVries, T.; Sheikh, N. A.; Gomella, L. G.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save